Abeona Therapeutics Inc (ABEO) FinancialsABEOFinancialAbeona Therapeutics Inc

Evaluating the bottom line, Abeona Therapeutics Inc maintains a gross margin of 63.30%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -119.97%, while the net margin is -177.43%. These profitability ratios, combined with a Return on Equity (ROE) of -43.13%, provide a clear picture of how effectively ABEO converts its operational activities into shareholder value.

In the context of the broader market, ABEO competes directly with industry leaders such as STRO and IKT. With a market capitalization of $342.25M, it holds a significant position in the sector. When comparing efficiency, ABEO's gross margin of 63.30% stands against STRO's 100.00% and IKT's N/A. Such benchmarking helps identify whether Abeona Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Abeona has shown a significant revenue increase, with Q2 2026 revenue at $11.4 million, up 31% from Q1. However, it also reported a net loss of $20.19 million for Q2, highlighting ongoing financial challenges.